Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
### Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure disorders and anxiety.
### Adult Dosing
* **Lennox-Gastaut Syndrome:** Initial dose is 5 mg twice daily.
* Titrate dose by 5-10 mg per day every week based on clinical response and tolerability.
* Maximum recommended dose: 20 mg twice daily.
### Pediatric Dosing (2 to 18 years)
* **Lennox-Gastaut Syndrome:** Initial dose is 5 mg twice daily.
* Titrate dose by 5-10 mg per day every week based on clinical response and tolerability.
* Maximum recommended dose: 20 mg twice daily.
* **Note:** Clobazam is not recommended for use in children younger than 2 years due to safety and efficacy concerns.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustments are established, but lower doses may be warranted.
* **Concomitant Medications:** Consider dose reduction of clobazam if used with strong CYP3A4 inhibitors. Consider dose adjustments of other CNS depressants.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, aggression, irritability, constipation, decreased appetite, rash, ataxia, drowsiness, behavioral problems.
* **Serious:** Suicidal ideation and behavior, severe skin reactions (e.g., Stevens-Johnson syndrome), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions.
### Key Drug Interactions
* **CYP2C19 Substrates:** Clobazam is a moderate inhibitor of CYP2C19. May increase concentrations of drugs like citalopram, escitalopram, omeprazole, and phenytoin. Monitor for increased toxicity of CYP2C19 substrates.
* **CNS Depressants:** Additive CNS depression when used with alcohol, opioids, other benzodiazepines, sedating antihistamines, or antipsychotics.
* **Phenobarbital, Phenytoin, Primidone:** Clobazam may increase levels of these antiepileptic drugs.
### Monitoring
* Monitor for therapeutic response (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of withdrawal.
* Monitor for signs of serious skin reactions.
* If concomitant antiepileptic drugs are used, monitor their serum concentrations if clinically indicated.
### Clinical Pearls
* Clobazam should be titrated slowly to minimize adverse effects.
* Withdrawal symptoms can occur upon abrupt discontinuation. Taper the dose gradually.
* Rash can be a dose-limiting toxicity. Discontinue clobazam if a severe rash develops.
* The active metabolite, N-desmethylclobazam (norclobazam), has a longer half-life than clobazam and contributes to its overall activity.
---
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for any questions regarding a medical condition or treatment.*
